{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
Scar Diminishing Cream by Guangzhou Hanhai Trading Co., Ltd
(2023)
Source URL:
First approved in 2023
Source:
Scar Diminishing Cream by Guangzhou Hanhai Trading Co., Ltd
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
Source:
NADA141571
(2023)
Source URL:
First approved in 2023
Source:
NADA141571
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Molidustat also was known as BAY 85-3934 is a novel inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) which stimulates erythropoietin (EPO) production and the formation of red blood cells. Hypoxia-inducible factor (HIF) is the major transcription factor involved in erythropoietin gene expression. Because oxygen-dependent degradation of the α subunit of HIF suppresses erythropoietin expression, stimulation of erythropoiesis by agents that prevent degradation of HIF has been one strategy for managing anemia. Thus, molidustat is in phase II of a clinical trial to investigate the effects therapy in patients with renal anemia associated with chronic kidney disease and/or end-stage renal disease.
Status:
Possibly Marketed Outside US
Source:
M006
(2023)
Source URL:
First approved in 2023
Source:
M006
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
Source:
NGA ALCOHOL WIPES SANDSTONE by NEVER GO ALONE
(2023)
Source URL:
First approved in 2023
Source:
NGA ALCOHOL WIPES SANDSTONE by NEVER GO ALONE
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2023)
Source URL:
First approved in 2023
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
ANDA075357
(2023)
Source URL:
First approved in 2023
Source:
ANDA075357
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
Status:
Possibly Marketed Outside US
Source:
EnLyte Extra-LN by Jaymac Pharmacueticals LLC
Source URL:
First approved in 2023
Source:
Biopar delta-FORTE by Jaymac Pharma
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
Source:
Quit Smoking Patch by Guangzhou Hanhai Trading Co., Ltd
(2023)
Source URL:
First approved in 2023
Source:
Quit Smoking Patch by Guangzhou Hanhai Trading Co., Ltd
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2023)
Source URL:
First approved in 2023
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(2023)
Source URL:
First approved in 2023
Source:
505G(a)(3)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
